Juan W. Valle

50.3k total citations · 14 hit papers
443 papers, 20.3k citations indexed

About

Juan W. Valle is a scholar working on Oncology, Surgery and Epidemiology. According to data from OpenAlex, Juan W. Valle has authored 443 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 333 papers in Oncology, 185 papers in Surgery and 163 papers in Epidemiology. Recurrent topics in Juan W. Valle's work include Pancreatic and Hepatic Oncology Research (158 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (157 papers) and Neuroendocrine Tumor Research Advances (150 papers). Juan W. Valle is often cited by papers focused on Pancreatic and Hepatic Oncology Research (158 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (157 papers) and Neuroendocrine Tumor Research Advances (150 papers). Juan W. Valle collaborates with scholars based in United Kingdom, United States and France. Juan W. Valle's co-authors include Ángela Lamarca, Rachna T. Shroff, John Bridgewater, Rishi Surana, Jonathan D. Mizrahi, Harpreet Wasan, David Cunningham, Mairéad G. McNamara, Daniel H. Palmer and Alan Anthoney and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Juan W. Valle

421 papers receiving 20.0k citations

Hit Papers

Cisplatin plus Gemcitabin... 2009 2026 2014 2020 2010 2011 2020 2009 2021 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
    2010 3.0k citations Juan W. Valle, Harpreet Wasan et al. profile →
  2. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
    2011 1.8k citations Éric Raymond, Jean‐Luc Raoul et al. profile →
  3. Pancreatic cancer
    2020 1.7k citations Juan W. Valle et al. profile →
  4. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    2009 602 citations David Cunningham, Juan W. Valle et al. Journal of Clinical Oncology profile →
  5. Biliary tract cancer
    2021 594 citations Juan W. Valle et al. profile →
  6. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2016 471 citations Juan W. Valle, Ivan Borbath et al. profile →
  7. New Horizons for Precision Medicine in Biliary Tract Cancers
    2017 425 citations Juan W. Valle, Ángela Lamarca et al. profile →
  8. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
    2017 303 citations Anders Sundin, Rudolf Arnold et al. Neuroendocrinology profile →
  9. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
    2019 285 citations Melinda Bachini, Tanios Bekaii‐Saab et al. Journal of Clinical Oncology profile →
  10. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 278 citations John Bridgewater, Julien Edeline et al. profile →
  11. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
    2020 248 citations Ángela Lamarca, Jorge Barriuso et al. Journal of Hepatology profile →
  12. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
    2022 159 citations Takuji Okusaka, Juan W. Valle et al. Journal of Clinical Oncology profile →
  13. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
    2023 147 citations Juan W. Valle, Robin Kate Kelley et al. Journal of Hepatology profile →
  14. European Neuroendocrine Tumour Society ( ENETS ) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
    2023 96 citations Andreas Kjær, Aurel Perren et al. Journal of Neuroendocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juan W. Valle United Kingdom 59 14.0k 9.8k 6.3k 4.8k 3.0k 443 20.3k
Pascal Hammel France 65 12.1k 0.9× 5.7k 0.6× 3.6k 0.6× 5.8k 1.2× 1.8k 0.6× 367 15.8k
Takuji Okusaka Japan 65 10.7k 0.8× 6.3k 0.6× 4.7k 0.8× 5.3k 1.1× 3.4k 1.1× 534 19.6k
Volkan Adsay United States 74 19.3k 1.4× 12.3k 1.3× 4.4k 0.7× 5.2k 1.1× 5.7k 1.9× 339 24.9k
Valérie Boige France 63 9.5k 0.7× 5.7k 0.6× 6.2k 1.0× 2.1k 0.4× 2.5k 0.8× 287 17.6k
Patrick Schöffski Belgium 68 9.6k 0.7× 3.2k 0.3× 9.5k 1.5× 1.5k 0.3× 4.8k 1.6× 510 19.4k
Manisha H. Shah United States 53 7.7k 0.5× 2.4k 0.2× 3.3k 0.5× 4.8k 1.0× 4.3k 1.4× 203 18.0k
Robert D. Odze United States 70 5.7k 0.4× 8.6k 0.9× 5.5k 0.9× 3.8k 0.8× 2.1k 0.7× 303 16.6k
David P. Kelsen United States 72 8.9k 0.6× 4.2k 0.4× 6.3k 1.0× 1.7k 0.3× 3.1k 1.0× 292 14.6k
Emilio Bajetta Italy 55 10.4k 0.7× 1.9k 0.2× 5.8k 0.9× 2.4k 0.5× 3.9k 1.3× 325 16.6k
Ross A. Abrams United States 54 10.0k 0.7× 6.0k 0.6× 6.3k 1.0× 3.0k 0.6× 1.3k 0.4× 181 14.5k

Countries citing papers authored by Juan W. Valle

Since Specialization
Citations

This map shows the geographic impact of Juan W. Valle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan W. Valle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan W. Valle more than expected).

Fields of papers citing papers by Juan W. Valle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan W. Valle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan W. Valle. The network helps show where Juan W. Valle may publish in the future.

Co-authorship network of co-authors of Juan W. Valle

This figure shows the co-authorship network connecting the top 25 collaborators of Juan W. Valle. A scholar is included among the top collaborators of Juan W. Valle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan W. Valle. Juan W. Valle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiao, Lianchun, Mitesh J. Borad, Robin Kate Kelley, et al.. (2025). Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials. Cancer. 132(1). e70227–e70227.
2.
Brand, Douglas, Juan W. Valle, Harpreet Wasan, et al.. (2024). The Effect of Tumor Biological Effective Dose (BED) on Stereotactic Body Radiotherapy (SBRT) Outcomes for Locally Advanced Cholangiocarcinoma (CCA): An Analysis of the ABC-07 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 120(2). S142–S143.
3.
Hawkins, M., Juan W. Valle, Harpreet Wasan, et al.. (2024). Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial.. Journal of Clinical Oncology. 42(16_suppl). 4006–4006. 5 indexed citations
4.
Rushbrook, Simon, Timothy J. Kendall, Yoh Zen, et al.. (2023). British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 73(1). 16–46. 33 indexed citations
5.
Hubner, Richard, et al.. (2023). Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. Therapeutic Advances in Medical Oncology. 15. 2601606–2601606. 7 indexed citations
6.
7.
Foy, Victoria, Mairéad G. McNamara, Juan W. Valle, et al.. (2023). Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current Oncology. 30(9). 8665–8685. 1 indexed citations
8.
Faluyi, Olusola Olusesan, Ángela Lamarca, Richard Hubner, et al.. (2023). Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes. Cancers. 15(11). 3047–3047.
9.
Graham, Kathryn, et al.. (2023). Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data. Immunotherapy. 15(7). 517–530. 3 indexed citations
10.
11.
12.
Merola, Elettra, Aurel Perren, Anja Rinke, et al.. (2022). High rate of Ki‐67 increase in entero‐pancreatic NET relapses after surgery with curative intent. Journal of Neuroendocrinology. 34(10). e13193–e13193. 9 indexed citations
13.
Koessler, Thibaud, María Alsina, Dirk Arnold, et al.. (2021). Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. British Journal of Cancer. 125(7). 911–919. 3 indexed citations
14.
McNamara, Mairéad G., Lipika Goyal, Mark Doherty, et al.. (2020). NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology. 16(16). 1069–1081. 11 indexed citations
15.
McNamara, Mairéad G., et al.. (2020). Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology. 20(8). 1682–1688. 19 indexed citations
16.
McNamara, Mairéad G., Andre Lopes, Harpreet Wasan, et al.. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology. 73(5). 1109–1117. 29 indexed citations
17.
Sundin, Anders, Rudolf Arnold, Éric Baudin, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology. 105(3). 212–244. 303 indexed citations breakdown →
18.
García‐Carbonero, Rocio, Anja Rinke, Juan W. Valle, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology. 105(3). 281–294. 82 indexed citations
19.
Galdy, Salvatore, Ángela Lamarca, Mairéad G. McNamara, et al.. (2016). HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews. 36(1). 141–157. 153 indexed citations
20.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pascal Hammel Breakdown of academic impact, for papers by Takuji Okusaka Breakdown of academic impact, for papers by Volkan Adsay Breakdown of academic impact, for papers by Valérie Boige Breakdown of academic impact, for papers by Patrick Schöffski Breakdown of academic impact, for papers by Manisha H. Shah Breakdown of academic impact, for papers by Robert D. Odze Breakdown of academic impact, for papers by David P. Kelsen Breakdown of academic impact, for papers by Emilio Bajetta Breakdown of academic impact, for papers by Ross A. Abrams
Rankless by CCL
2026